CL2022002379A1 - Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso. - Google Patents
Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso.Info
- Publication number
- CL2022002379A1 CL2022002379A1 CL2022002379A CL2022002379A CL2022002379A1 CL 2022002379 A1 CL2022002379 A1 CL 2022002379A1 CL 2022002379 A CL2022002379 A CL 2022002379A CL 2022002379 A CL2022002379 A CL 2022002379A CL 2022002379 A1 CL2022002379 A1 CL 2022002379A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- nucleic acid
- sin
- short interfering
- acid molecule
- Prior art date
Links
- 230000002452 interceptive effect Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986150P | 2020-03-06 | 2020-03-06 | |
| US202063109196P | 2020-11-03 | 2020-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002379A1 true CL2022002379A1 (es) | 2023-07-28 |
Family
ID=75278356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002379A CL2022002379A1 (es) | 2020-03-06 | 2022-09-01 | Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20220364096A1 (OSRAM) |
| EP (1) | EP4121533A1 (OSRAM) |
| JP (1) | JP2023515664A (OSRAM) |
| KR (1) | KR20220163960A (OSRAM) |
| CN (1) | CN115485384A (OSRAM) |
| AU (1) | AU2021230601A1 (OSRAM) |
| BR (1) | BR112022017287A2 (OSRAM) |
| CA (1) | CA3170466A1 (OSRAM) |
| CL (1) | CL2022002379A1 (OSRAM) |
| CO (1) | CO2022014258A2 (OSRAM) |
| GE (2) | GEP20257742B (OSRAM) |
| IL (1) | IL296045A (OSRAM) |
| MX (1) | MX2022011012A (OSRAM) |
| PE (1) | PE20221578A1 (OSRAM) |
| PH (1) | PH12022552163A1 (OSRAM) |
| TW (1) | TW202208625A (OSRAM) |
| WO (1) | WO2021178885A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202002149XA (en) * | 2017-09-14 | 2020-04-29 | Janssen Biopharma Inc | Galnac derivatives |
| GEP20257742B (en) * | 2020-03-06 | 2025-03-10 | Aligos Therapeutics Inc | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| CA3197470A1 (en) | 2020-10-21 | 2022-04-28 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2023088227A1 (zh) | 2021-11-16 | 2023-05-25 | 上海舶望制药有限公司 | 抑制血管紧张素原(agt)蛋白表达的组合物和方法 |
| WO2023122317A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
| US20230399645A1 (en) * | 2022-05-16 | 2023-12-14 | University Of Massachusetts | Optimized sirna scaffolds |
| EP4541804A1 (en) * | 2022-06-14 | 2025-04-23 | Rona Bioscience, Limited | Cyclic phosphonate-modified nucleotide |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| EP4634152A1 (en) | 2022-12-15 | 2025-10-22 | Syngenta Crop Protection AG | Novel bicyclic-carboxamide compounds useful as pesticides |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| AU2024212652A1 (en) * | 2023-01-26 | 2025-07-10 | Aligos Therapeutics, Inc. | Hepatitis b combination therapies |
| WO2024173593A1 (en) * | 2023-02-14 | 2024-08-22 | Basecure Therapeutics | Modified double stranded rna agents |
| WO2024254091A1 (en) * | 2023-06-05 | 2024-12-12 | Empirico Inc. | Treatment of fgg related diseases and disorders |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| CN117024485B (zh) * | 2023-08-11 | 2026-02-13 | 江苏申基生物科技有限公司 | 一种2’-OMe腺苷的合成方法 |
| IL327476A (en) * | 2023-11-03 | 2026-05-01 | Basecure Therapeutics Llc | Modified oligonucleotides and methods for using them |
| WO2025104032A1 (en) | 2023-11-14 | 2025-05-22 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
| PY2501648A (es) | 2024-01-12 | 2025-10-31 | Syngenta Crop Protection Ag | Nuevos compuestos de carboxamida |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025201529A1 (en) * | 2024-03-29 | 2025-10-02 | Ractigen Therapeutics | Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof |
| WO2025240506A1 (en) | 2024-05-14 | 2025-11-20 | Aligos Therapeutics, Inc. | Modified antisense oligonucleotides for treating hepatitis b virus |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| CN120796266A (zh) * | 2024-07-08 | 2025-10-17 | 北京悦康科创医药科技股份有限公司 | 一种降低hbv基因表达的反义寡核苷酸及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002944A1 (en) * | 2007-06-22 | 2008-12-31 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| EP2437752A2 (en) * | 2009-06-03 | 2012-04-11 | Dicerna Pharmaceuticals, Inc. | Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
| EP2601204B1 (en) | 2010-04-28 | 2016-09-07 | Ionis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| JP6165723B2 (ja) * | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 |
| IL303831A (en) * | 2011-11-18 | 2023-08-01 | Alnylam Pharmaceuticals Inc | Adapted RNAI factors |
| CA2939822C (en) * | 2014-02-18 | 2018-09-25 | Osaka University | Crosslinked nucleoside and nucleotide |
| KR20180038465A (ko) * | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| SG11201804729RA (en) * | 2015-12-07 | 2018-07-30 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| JP2018536689A (ja) * | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| JP6989521B2 (ja) | 2016-09-02 | 2022-01-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 標的化リガンド |
| WO2018045317A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| RS63836B1 (sr) * | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
| CN110997919B (zh) * | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| CN118638788A (zh) * | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| EP3790970A1 (en) * | 2018-05-07 | 2021-03-17 | Alnylam Pharmaceuticals Inc. | Extrahepatic delivery |
| WO2019217397A2 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
| MX2021005357A (es) | 2018-11-08 | 2021-06-30 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos. |
| GEP20257742B (en) * | 2020-03-06 | 2025-03-10 | Aligos Therapeutics Inc | Modified short interfering nucleic acid (sina) molecules and uses thereof |
-
2021
- 2021-03-05 GE GEAP202116053A patent/GEP20257742B/en unknown
- 2021-03-05 EP EP21715377.4A patent/EP4121533A1/en active Pending
- 2021-03-05 US US17/194,079 patent/US20220364096A1/en active Pending
- 2021-03-05 GE GEAP202416053A patent/GEAP202416053A/en unknown
- 2021-03-05 TW TW110108015A patent/TW202208625A/zh unknown
- 2021-03-05 AU AU2021230601A patent/AU2021230601A1/en active Pending
- 2021-03-05 IL IL296045A patent/IL296045A/en unknown
- 2021-03-05 BR BR112022017287A patent/BR112022017287A2/pt unknown
- 2021-03-05 PH PH1/2022/552163A patent/PH12022552163A1/en unknown
- 2021-03-05 CN CN202180032666.3A patent/CN115485384A/zh active Pending
- 2021-03-05 JP JP2022552538A patent/JP2023515664A/ja active Pending
- 2021-03-05 MX MX2022011012A patent/MX2022011012A/es unknown
- 2021-03-05 KR KR1020227034100A patent/KR20220163960A/ko active Pending
- 2021-03-05 CA CA3170466A patent/CA3170466A1/en active Pending
- 2021-03-05 PE PE2022001900A patent/PE20221578A1/es unknown
- 2021-03-05 WO PCT/US2021/021199 patent/WO2021178885A1/en not_active Ceased
-
2022
- 2022-02-15 US US17/672,268 patent/US11549110B2/en active Active
- 2022-09-01 CL CL2022002379A patent/CL2022002379A1/es unknown
- 2022-10-05 CO CONC2022/0014258A patent/CO2022014258A2/es unknown
- 2022-11-29 US US18/059,561 patent/US20230332153A1/en active Pending
-
2023
- 2023-07-28 US US18/361,363 patent/US12129469B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202416053A (en) | 2024-10-10 |
| BR112022017287A2 (pt) | 2022-11-16 |
| KR20220163960A (ko) | 2022-12-12 |
| US12129469B2 (en) | 2024-10-29 |
| PE20221578A1 (es) | 2022-10-06 |
| AU2021230601A1 (en) | 2022-10-06 |
| CO2022014258A2 (es) | 2022-12-30 |
| WO2021178885A1 (en) | 2021-09-10 |
| PH12022552163A1 (en) | 2024-01-29 |
| US20230365970A1 (en) | 2023-11-16 |
| AU2021230601A2 (en) | 2022-10-20 |
| US20230332153A1 (en) | 2023-10-19 |
| US20220177888A1 (en) | 2022-06-09 |
| CA3170466A1 (en) | 2021-09-10 |
| IL296045A (en) | 2022-10-01 |
| JP2023515664A (ja) | 2023-04-13 |
| GEP20257742B (en) | 2025-03-10 |
| TW202208625A (zh) | 2022-03-01 |
| US11549110B2 (en) | 2023-01-10 |
| EP4121533A1 (en) | 2023-01-25 |
| CN115485384A (zh) | 2022-12-16 |
| MX2022011012A (es) | 2022-10-07 |
| US20220364096A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007852A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| CL2022001670A1 (es) | Inhibidores de proteínas kras mutantes | |
| BR112022017986A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| MX2021003771A (es) | Analisis de analitos multiples usando un ensayo unico. | |
| CO2020010303A2 (es) | Conjugados de il-15, y sus usos | |
| BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
| CR10069A (es) | Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas | |
| ECSP099027A (es) | Anticuerpos anti-dll4 y métodos que los usan | |
| JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
| CO2018011856A2 (es) | Composiciones, métodos y kits para la síntesis y detección de ácidos nucleicos | |
| BR112017012351A2 (pt) | compostos inibidores de bcl xl que têm permeabilidade celular baixa e conjugados de fármaco-anticorpo que incluem os mesmos | |
| GT201000088A (es) | 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
| BRPI0814343A2 (pt) | Materiais e métodos para a seleção da sexagem do esperma | |
| PA8618901A1 (es) | Biaril sulfonamidas y metodo para el uso de las mismas | |
| BR112019013468A8 (pt) | Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos | |
| MX2021015156A (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. | |
| MX2020008125A (es) | Composiciones que comprenden berberina. | |
| DOP2025000104A (es) | Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas | |
| BR112017013277A2 (pt) | composição aquosa, método de amplificação isotérmica de ácido nucleico e kit | |
| CL2024003614A1 (es) | Molécula de unión multiespecífica anti-btc/vegf; composición farmacéutica; y su uso. | |
| MX2021010254A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. | |
| BR112021017551A2 (pt) | Uso de vírus oncolíticos para o tratamento de câncer | |
| MX2021003760A (es) | Identificacion y analisis de muestras microbianas por incubacion rapida y enriquecimiento de acido nucleico. | |
| AR103576A1 (es) | Molécula sustrato | |
| CY1108840T1 (el) | Μεθοδοι και συνθεσεις για το χαρακτηρισμο ενος ενζυμου συστηματος οξειδοαναγωγικου αντιδραστηριου |